Gene-expression profiling of adrenocortical carcinoma

Expert Review of Molecular Diagnostics

Volumn 9, Issue 4, 2009, Pages 343-351

  Suh, Insoo ^a   Guerrero, Marlon A ^a   Kebebew, Electron ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenal incidentaloma; Adrenalectomy; Adrenocortical carcinoma; Diagnostic marker; Gene expression profiling; Prognostic marker

Indexed keywords

MITOTANE;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEXAMETHASONE SUPPRESSION TEST; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; LOW DRUG DOSE; METASTASIS; MICROARRAY ANALYSIS; PROGNOSIS; REVIEW; TUMOR DIAGNOSIS; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; COMBINED MODALITY THERAPY; GARDNER SYNDROME; GENE EXPRESSION PROFILING; GENES, APC; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; LOSS OF HETEROZYGOSITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 66449084207     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.13     Document Type: Review

References (56)

1. Gonzalez RJ, Tamm EP, Ng C et al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery 142(6), 867-875; discussion 867-875 (2007).
2. Icard P, Goudet P, Charpenay C et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J. Surg. 25(7), 891-897 (2001).
3. Kendrick ML, Lloyd R, Erickson L et al. Adrenocortical carcinoma: surgical progress or status quo? Arch. Surg. 136(5), 543-549 (2001).
4. Paton BL, Novitsky YW, Zerey M et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 140(6), 914-920; discussion 919-920 (2006).
5. Schteingart DE, Doherty GM, Gauger PG et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer 12(3), 667-680 (2005).
6. Sidhu S, Sywak M, Robinson B, Delbridge L. Adrenocortical cancer: recent clinical and molecular advances. Curr. Opin. Oncol. 16(1), 13-18 (2004).
7. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 91(6), 2027-2037 (2006).
8. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens. State Sci. Statements 19(2), 1-25 (2002).
9. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J. Surg. 30(5), 872-878 (2006).
10. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med. 356(6), 601-610 (2007).
11. Caoili EM, Korobkin M, Francis IR et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222(3), 629-633 (2002).
12. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 25(2), 309-340 (2004).
13. Shen WT, Sturgeon C, Duh QY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J. Surg. Oncol. 89(3), 186-192 (2005).
14. Sturgeon C, Kebebew E. Laparoscopic adrenalectomy for malignancy. Surg. Clin. North Am. 84(3), 755-774 (2004).
15. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J. Am. Coll. Surg. 202(3), 423-430 (2006).
16. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223(10), 1109-1112 (1973).
17. Terzolo M, Angeli A, Fassnacht M et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356(23), 2372-2380 (2007).
18. Berruti A, Terzolo M, Sperone P et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr. Relat. Cancer 12(3), 657-666 (2005).
19. Khan TS, Imam H, Juhlin C et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann. Oncol. 11(10), 1281-1287 (2000).
20. Fareau GG, Lopez A, Stava C, Vassilopoulou-Sellin R. Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anticancer Drugs 19(6), 637-644 (2008).
21. Duh QY. Functioning and non-functioning adrenal tumors. In: The Practice of General Surgery. Bland KI (Ed.). WB Saunders, PA, USA, 1077-1082 (2002).
22. Kebebew E, Siperstein AE, Clark OH, Duh QY. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch. Surg. 137(8), 948-951; discussion 952-1943 (2002).
23. Kebebew E, Duh QY. Adrenal incidentaloma. In: Current Surgical Therapy. Cameron JL (Ed.). Elsevier Mosby, PA USA, 575-579 (2004).
24. Heaston DK, Handel DB, Ashton PR, Korobkin M. Narrow gauge needle aspiration of solid adrenal masses. AJR Am. J. Roentgenol. 138(6), 1143-1148 (1982).
25. Berkman WA, Bernardino ME, Sewell CW, Price RB, Sones PJ Jr. The computed tomography-guided adrenal biopsy. An alternative to surgery in adrenal mass diagnosis. Cancer 53(10), 2098-2103 (1984).
26. Katz RL, Patel S, Mackay B, Zornoza J. Fine needle aspiration cytology of the adrenal gland. Acta Cytol. 28(3), 269-282 (1984).
27. Welch TJ, Sheedy PF 2nd, Stephens DH, Johnson CM, Swensen SJ. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology 193(2), 341-344 (1994).
28. Silverman SG, Mueller PR, Pinkney LP, Koenker RM, Seltzer SE. Predictive value of image-guided adrenal biopsy: analysis of results of 101 biopsies. Radiology 187(3), 715-718 (1993).
29. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13(3), 202-206 (1989).
30. Aubert S, Wacrenier A, Leroy X et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol. 26(12), 1612-1619 (2002).
31. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M. Pathological and molecular features of adrenocortical carcinoma: an update. J. Clin. Pathol. 61(7), 787-793 (2008).
32. Soon PS, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 13(5), 548-561 (2008).
33. Heppner C, Reincke M, Agarwal SK et al. MEN1 gene analysis in sporadic adrenocortical neoplasms. J. Clin. Endocrinol. Metab. 84(1), 216-219 (1999).
34. Kjellman M, Roshani L, Teh BT et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J. Clin. Endocrinol. Metab. 84(2), 730-735 (1999).
35. Schulte KM, Mengel M, Heinze M et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J. Clin. Endocrinol. Metab. 85(1), 441-448 (2000).
36. Wachenfeld C, Beuschlein F, Zwermann O et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur. J. Endocrinol. 145(3), 335-341 (2001).
37. Sidhu S, Marsh DJ, Theodosopoulos G et al. Comparative genomic hybridization analysis of adrenocortical tumors. J. Clin. Endocrinol. Metab. 87(7), 3467-3474 (2002).
38. Zhao J, Speel EJ, Muletta-Feurer S et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am. J. Pathol. 155(4), 1039-1045 (1999).
39. Giordano TJ, Thomas DG, Kuick R et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 162(2), 521-531 (2003).
40. de Fraipont F, El Atifi M, Cherradi N et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 90(3), 1819-1829 (2005). •• Expression profile of candidate select genes in adrenocortical carcinoma were analyzed and prognostic markers identified.
41. Velazquez-Fernandez D, Laurell C, Geli J et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138(6), 1087-1094 (2005).
42. Slater EP, Diehl SM, Langer P et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur. J. Endocrinol. 154(4), 587-598 (2006).
43. Lombardi CP, Raffaelli M, Pani G et al. Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study. Biomed. Pharmacother. 60(4), 186-190 (2006).
44. West AN, Neale GA, Pounds S et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res. 67(2), 600-608 (2007).
45. Fernandez-Ranvier GG, Weng J, Yeh RF et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch. Surg. 143(9), 841-846; discussion 846 (2008). • Evaluated a relatively large number of benign and malignant adrenocortical tumors with accurate diagnostic markers identified and confirmed by quantitative PCR.
46. Rogers S, Cambrosio A. Making a new technology work: the standardization and regulation of microarrays. Yale J. Biol. Med. 80(4), 165-178 (2007).
47. Steinhoff C, Vingron M. Normalization and quantification of differential expression in gene expression microarrays. Brief Bioinform. 7(2), 166-177 (2006).
48. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4(7), 505-518 (2004).
49. Gicquel C, Bertagna X, Schneid H et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 78(6), 1444-1453 (1994).
50. Gicquel C, Bertagna X, Gaston V et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 61(18), 6762-6767 (2001).
51. Almeida MQ, Fragoso MC, Lotfi CF et al. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J. Clin. Endocrinol. Metab. 93(9), 3524-3531 (2008).
52. Barlaskar FM, Spalding AC, Heaton JH et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 94(1), 204-212 (2009). •• Comprehensive study demonstrating targeting of the IGF1 receptor in a preclinical model of adrenocortical carcinoma results in a significant antineoplastic effect.
53. Schmitt A, Saremaslani P, Schmid S et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 49(3), 298-307 (2006).
54. Fernandez-Ranvier GG, Weng J, Yeh RF et al. Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J. Surg. 32(5), 873-881 (2008).
55. de Reynies A, Assie G, Rickman DS et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27(7), 1108-1115 (2009). •• Large cohort of adrenocortical tumors that represent a clinical dilemma for diagnosis were distinct on gene-expression profile. The investigator also found gene-expression profile was an independent predictor of disease-free and overall survival in patients with adrenocortical carcinoma.
56. Giordano TJ, Kuick R, Else T et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15(2), 668-676 (2009). •• Follow-up study where gene-expression profiling by prinicipal component analysis was an independent predictor of survival.